462 related articles for article (PubMed ID: 24379606)
1. Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma.
Bacigalupo ML; Manzi M; Rabinovich GA; Troncoso MF
World J Gastroenterol; 2013 Dec; 19(47):8831-49. PubMed ID: 24379606
[TBL] [Abstract][Full Text] [Related]
2. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.
Li H; Wu K; Tao K; Chen L; Zheng Q; Lu X; Liu J; Shi L; Liu C; Wang G; Zou W
Hepatology; 2012 Oct; 56(4):1342-51. PubMed ID: 22505239
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of Galectin-1 and Galectin-3 in hepatocellular carcinoma.
Setayesh T; Colquhoun SD; Wan YY
Liver Res; 2020 Dec; 4(4):173-179. PubMed ID: 34567824
[TBL] [Abstract][Full Text] [Related]
4. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma.
Hsu DK; Dowling CA; Jeng KC; Chen JT; Yang RY; Liu FT
Int J Cancer; 1999 May; 81(4):519-26. PubMed ID: 10225438
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis.
Ma WL; Lai HC; Yeh S; Cai X; Chang C
Endocr Relat Cancer; 2014 Jun; 21(3):R165-82. PubMed ID: 24424503
[TBL] [Abstract][Full Text] [Related]
6. Lack of galectin-1 exacerbates chronic hepatitis, liver fibrosis, and carcinogenesis in murine hepatocellular carcinoma model.
Potikha T; Pappo O; Mizrahi L; Olam D; Maller SM; Rabinovich GA; Galun E; Goldenberg DS
FASEB J; 2019 Jul; 33(7):7995-8007. PubMed ID: 30897344
[TBL] [Abstract][Full Text] [Related]
7. Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14.
Cho Y; Lee YB; Lee JH; Lee DH; Cho EJ; Yu SJ; Kim YJ; Kim JI; Im JH; Lee JH; Oh EJ; Yoon JH
PLoS One; 2016; 11(8):e0160822. PubMed ID: 27494117
[TBL] [Abstract][Full Text] [Related]
8. [Expression and prognostic value of galectin-9 in hepatocellular carcinoma patients].
Gu CJ; Wu H; Sheng CY; Ni QC
Zhonghua Yi Xue Za Zhi; 2013 Jul; 93(26):2025-8. PubMed ID: 24169278
[TBL] [Abstract][Full Text] [Related]
9. Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment.
Vilchez V; Turcios L; Marti F; Gedaly R
World J Gastroenterol; 2016 Jan; 22(2):823-32. PubMed ID: 26811628
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
Jiang Y; Chen P; Hu K; Dai G; Li J; Zheng D; Yuan H; He L; Xie P; Tu M; Peng S; Qu C; Lin W; Chung RT; Hong J
J Cell Mol Med; 2021 Feb; 25(3):1568-1582. PubMed ID: 33410581
[TBL] [Abstract][Full Text] [Related]
11. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis.
Chen S; Pu J; Bai J; Yin Y; Wu K; Wang J; Shuai X; Gao J; Tao K; Wang G; Li H
J Exp Clin Cancer Res; 2018 Jan; 37(1):3. PubMed ID: 29316949
[TBL] [Abstract][Full Text] [Related]
12. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease.
Ma HY; Yamamoto G; Xu J; Liu X; Karin D; Kim JY; Alexandrov LB; Koyama Y; Nishio T; Benner C; Heinz S; Rosenthal SB; Liang S; Sun M; Karin G; Zhao P; Brodt P; Mckillop IH; Quehenberger O; Dennis E; Saltiel A; Tsukamoto H; Gao B; Karin M; Brenner DA; Kisseleva T
J Hepatol; 2020 May; 72(5):946-959. PubMed ID: 31899206
[TBL] [Abstract][Full Text] [Related]
13. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
Esparza-Baquer A; Labiano I; Sharif O; Agirre-Lizaso A; Oakley F; Rodrigues PM; Zhuravleva E; O'Rourke CJ; Hijona E; Jimenez-Agüero R; Riaño I; Landa A; La Casta A; Zaki MYW; Munoz-Garrido P; Azkargorta M; Elortza F; Vogel A; Schabbauer G; Aspichueta P; Andersen JB; Knapp S; Mann DA; Bujanda L; Banales JM; Perugorria MJ
Gut; 2021 Jul; 70(7):1345-1361. PubMed ID: 32907830
[TBL] [Abstract][Full Text] [Related]
14. The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis.
Berasain C; Avila MA
J Gastroenterol; 2014 Jan; 49(1):9-23. PubMed ID: 24318021
[TBL] [Abstract][Full Text] [Related]
15. Implication of the Hedgehog pathway in hepatocellular carcinoma.
Della Corte CM; Viscardi G; Papaccio F; Esposito G; Martini G; Ciardiello D; Martinelli E; Ciardiello F; Morgillo F
World J Gastroenterol; 2017 Jun; 23(24):4330-4340. PubMed ID: 28706416
[TBL] [Abstract][Full Text] [Related]
16. Correlation between serum galectin-9 levels and liver fibrosis.
Fujita K; Niki T; Nomura T; Oura K; Tadokoro T; Sakamoto T; Tani J; Yoneyama H; Morishita A; Kuroda N; Arai T; Nishimoto N; Himoto T; Hirashima M; Masaki T
J Gastroenterol Hepatol; 2018 Feb; 33(2):492-499. PubMed ID: 28618039
[TBL] [Abstract][Full Text] [Related]
17. Pathways and gene expression profiles in hepatocellular carcinoma.
Facciorusso A; Nacchiero MC; Rosania R; Laonigro G; Giorgio F; Del Prete V; Panella C; Ierardi E
Minerva Gastroenterol Dietol; 2012 Mar; 58(1):35-48. PubMed ID: 22419003
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of serum galectin-3 levels in patients with hepatocellular cancer and chronic viral hepatitis.
Ulu M; Alacacioglu A; Yuksel E; Pamukk BO; Bozkaya G; Ari A; Yuksel A; Sop G; Alacacioglu I
Saudi J Gastroenterol; 2015; 21(1):47-50. PubMed ID: 25672239
[TBL] [Abstract][Full Text] [Related]
19. SHP2 is induced by the HBx-NF-κB pathway and contributes to fibrosis during human early hepatocellular carcinoma development.
Kang HJ; Chung DH; Sung CO; Yoo SH; Yu E; Kim N; Lee SH; Song JY; Kim CJ; Choi J
Oncotarget; 2017 Apr; 8(16):27263-27276. PubMed ID: 28460481
[TBL] [Abstract][Full Text] [Related]
20. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.
Hernandez-Gea V; Toffanin S; Friedman SL; Llovet JM
Gastroenterology; 2013 Mar; 144(3):512-27. PubMed ID: 23313965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
